Development of health behaviour questionnaire for breast cancer women in Mainland China.
Hui Xu, Guichun Jiang, Xiujie Zhang and 3 others
PMID 33369265WHAT IT FOUND
A new 24-item questionnaire reliably measures health behaviours in breast cancer women on endocrine therapy.
It covers treatment, exercise, psychological adjustment, diet, and medical seeking. Use it to identify gaps in self-care and target education where patients are struggling.
Key findings
01The final Health Behaviour Questionnaire (HBQ) consists of 24 items across five domains: treatment behaviour, exercise behaviour, psychological adjustment, diet behaviour, and active medical-seeking behaviour.
02The questionnaire demonstrated strong internal consistency (Cronbach's alpha 0.934) and acceptable test-retest reliability (ICC 0.704) over a two-week interval.
03Confirmatory factor analysis supported the five-factor structure with good model fit indices (RMSEA = 0.069, CFI = 0.931).
STILL TO COME
How it was doneWhat they foundWhat it means for RNs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The study was conducted only in Mainland China, so the questionnaire's validity in other cultural or healthcare contexts is unknown. There was no 'gold standard' questionnaire available to compare against for criterion-related validity. The initial item reduction relied on expert and patient feedback, but deeper qualitative interviews with stakeholders were not conducted. The study population was restricted to women taking endocrine therapy for more than one month and excluding those with other serious comorbidities.
Declared interests
The authors declare no conflicts of interest. The study was funded by the Department of Science & Technology of Liaoning Province.
The easy way to misread this
Do not assume this questionnaire is validated for use outside of Mainland China or for breast cancer patients not on endocrine therapy. Its reliability and factor structure are specific to the Chinese women with hormone receptor-positive breast cancer studied here.